|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pulmonary and Critical Care Medicine (Dr. Dasgupta), Kelsey-Sebold Clinic, Houston, TX, and the Department of Pulmonary and Critical Care Medicine (Drs. Jain, Minai, and Sandur, Ms. Meli, and Drs. Arroliga and Mehta), Cleveland Clinic Foundation, Cleveland, OH.
Correspondence to: Atul C. Mehta, MBBS, FCCP, Department of Pulmonary and Critical Care Medicine, Desk A-90, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195
| Abstract |
|---|
|
|
|---|
Objective: To compare the yield of conventional diagnostic procedures (CDP) (bronchial washing, bronchial brushing, and endobronchial forceps biopsy) with that obtained from a combination of CDP and TBNA (CDP + TBNA).
Design: Prospective study of 55 patients.
Setting: Tertiary-care referral hospital.
Results: Of the 55 patients in whom malignancy was confirmed, CDP + TBNA identified 53 (96%) vs 42 (76%) identified by CDP (p = 0.001). The highest yield from any individual procedure was obtained by TBNA. Of the 23 patients with SPD, 22 (96%) were diagnosed using CDP + TBNA compared with 15 (65%) by CDP (p = 0.016); the yield from TBNA alone (22 of 23) in this group surpassed the combined yield from all other procedures. Although no statistically significant difference in yield was observed for EML, the use of TBNA identified four additional patients compared with CDP.
Conclusion: We conclude that the addition of TBNA to CDP increases diagnostic yield in patients with visible endobronchial lesions.
Key Words: endobronchial lesion exophytic mass lesion submucosal and peribronchial disease transbronchial needle aspiration
| Introduction |
|---|
|
|
|---|
| Materials and Methods |
|---|
|
|
|---|
All patients had bronchial washings (BW), brush biopsy (BB), EBB, and TBNA. The procedural sequence between EBB and TBNA was randomly allocated to either of the two sequences: (1) BW, EBB, TBNA, and BB, or (2) BW, TBNA, EBB, and BB. Four adequate EBB specimens and two passes with the cytology needle (21- or 22-gauge; Mill-Rose Lab, Inc; Mentor, OH) were performed. Specimen handling, cytopathology evaluation, and technical details of TBNA have been described elsewhere.1 Both smear preparation and flushed aspirates were sent for cytology; rapid on-site cytology evaluation was not performed. For obtaining specimens from EML, the needle was directly inserted into the lesion, avoiding necrotic areas as practiced with other CDP. For submucosal lesions, the needle was partially introduced at an angle of 45° into the bronchial wall, whereas complete penetration through the wall was performed in the case of extrinsic compression from peribronchial disease.1 The bronchoscopic findings were correlated with the anatomic location of the peribronchial lesion on CT scans of the chest, when available. BW and BB were performed in a conventional fashion. Cytologic analysis was considered positive only when large numbers of definitely malignant cells were present. Cellular atypia and abnormal cells highly suggestive of malignancy were considered as negative, because they failed to serve as diagnostic end points.
The primary outcome measure studied was the diagnostic yield comparing CDP (combination of BW, BB, and EBB) with CDP + TBNA. Furthermore, we analyzed the impact on diagnostic yield from each of the individual procedures as well as on the basis of the nature of the lesion, ie, EML or SPD. We also studied whether presence of lesion in upper lobes and sequence of performing TBNA and EBB influenced diagnostic yield. Any procedure-related complications and damage to the bronchoscope were also documented.
Statistical analysis of the difference in diagnostic yield between the two groups was performed using McNemar's test. Fisher's Exact Test was used to detect any difference between locations and procedure sequence. A p value < 0.05 was considered to be significant.
| Results |
|---|
|
|
|---|
|
For the 55 eligible patients, the diagnostic yields from CDP and CDP + TBNA are depicted in Table 1 . There was a significant increase in diagnostic yield with the addition of TBNA (CDP, 76%; CDP + TBNA, 96%; p = 0.001), primarily resulting from differences in the SPD group (CPD, 65%; CPD+TBNA, 96%; p = 0.016). Although no statistical difference was observed in the EML group, TBNA did identify four additional patients with lung cancer.
|
|
Analysis of diagnostic yield as a function of location of the lesion is shown in Table 3 . Of the 55 lesions, 25 (45%) were in the upper lobes: 15 (27%) in the right upper lobes and 10 (18%) in the left upper lobes. The addition of TBNA increased yield irrespective of the location of the lesion in the upper or other lobes. However, there was no statistical advantage in performing TBNA in the upper lobes compared with other lobes. Nor were there any differences in yield observed within the CDP group between the upper and other lobes. Similarly, no difference in diagnostic yield was seen whether TBNA was performed before or after EBB (Table 4 ).
|
|
| Discussion |
|---|
|
|
|---|
Submucosal disease, as defined earlier, and peribronchial disease presenting as narrowing and extrinsic compression, on the other hand, have significantly lower yields with CDP.6 8 9 Although Lundgreen et al9 reported a greater yield with EBB than TBNA (69% vs 46%), in two other studies, these trends were reversed.6 8 Shure and Fedullo6 showed an increased yield with TBNA (71%) compared with EBB (55%), similar to results obtained by Buirski et al8 (EBB, 43%; TBNA, 100%). The individual yield from EBB and TBNA in our series (EBB, 43%; TBNA, 85%) is similar to that reported in the latter series.
The addition of TBNA to CDP increased the diagnostic yield in our series. In submucosal disease, involvement tends to occur in a submucosal plane along the lymphatics with minimal mucosal abnormality. Similarly, extrinsic compression from peribronchial disease tends to leave the mucosal surface predominantly intact. Conventional procedures using EBB or BB tend to sample mainly the surface rather than deep within the lesion. In these situations, the ability of TBNA to provide adequate sampling by penetrating either the submucosa or directly through the bronchial wall into the tumor mass could enhance diagnostic yield. Our diagnostic yield of 65% with CDP, compared with the 96% yield obtained by the addition of TBNA, is probably a reflection of this anatomic variation that occurs with SPD. Similar reasoning probably explains a negative TBNA result in the patient with carcinoma in situ, in whom EBB was the only positive result.
A similar increase in diagnostic yield was observed in EML when TBNA was added to CDP. Although this increase did not reach statistical significance, it diagnosed lung cancer in four additional patients. The potential for TBNA to bypass surface necrosis and sample viable tumor from deep within the mass is a possible explanation. Moreover, the particular cell type of the tumor could influence yield from EBB. Crush artifacts produced during biopsy sampling of small cell cancer may result in a negative result. This situation was seen in two of the cases in which TBNA was exclusively diagnosed. Jones et al13 have similarly reported on the critical diagnostic value of TBNA in five patients with small cell cancer who demonstrated crush artifacts on nondiagnostic EBB.
Analysis of yield from individual procedures and their combinations revealed several interesting facts. The best yield from any individual procedure was obtained with TBNA. In SPD, the yield from TBNA was far superior to the yield from any other individual procedure or their combination. Thus, use of TBNA alone or in combination with CDP would have diagnosed disease in all these patients, ie, the critical information was provided by TBNA alone. In EML, progressively higher yield was obtained by the addition of TBNA to EBB and BB, with the best results being obtained by a combination of EBB, BB, and TBNA. BW provided the least diagnostic information and were never positive when any of the other test results were negative. The ability of BW to enhance yield has been questioned before. Kvale et al7 found no additional advantage in performing BW when forceps biopsy and BB were simultaneously performed. However, as shown in Table 2 , the addition of BW did increase the yield in EML from 26 to 27 of 32 cases (81 to 84%) and in SPD from 14 to 15 of 23 cases (61 to 65%) if TBNA was not performed. Thus, if TBNA is used as part of the sampling procedures, there is no advantage in performing simultaneous BW.
We also analyzed diagnostic yield as a function of the location of the lesion. Traditionally, lesions in upper lobes are often technically difficult to access because of the acute angulation of the bronchoscope needed to reach them, thus restricting adequate sampling by the forceps. Buirski et al8 have reported on 28 upper lobe lesions, 17 of which were proximal at the lobar orifice, 11 being distal. Of the 17 proximal lesions, 14 were diagnosed by EBB, but only 4 of 11 distal lesions were identified by the EBB compared with 10 of 11 by TBNA. In our series, however, there was no difference in the yield among CDP with respect to location of the lesion in the upper lobes. The addition of TBNA, on the other hand, significantly increased the diagnostic yield from these areas, as well as from other lobes.
No significant complications, either related to the procedure or to bronchoscopic damage, were observed with the use of TBNA.
TBNA was exclusively diagnostic in 20% of patients, such that overall diagnostic yield was increased from 76 to 96%, and subset yields from 84 to 97% in EML, and from 65 to 96% in SPD. This has implications not only from a cost point of view, but more importantly from the perspective of improving patient care by rendering earlier diagnosis and treatment plans and reducing the morbidity from subsequent repeat or new procedures needed to obtain final diagnosis.
Based on the diagnostic yield obtained from this series, we conclude that TBNA is a safe procedure that should be routinely used to increase diagnostic yield in patients with EML or SPD. In patients with SPD, TBNA should be considered the procedure of choice. In EML, TBNA should be combined with EBB and BB to maximize yield, under which situation BW may be eliminated. Depending on the confidence level of the operator, BW may be collected and stored, and analyzed only if all other test results are negative. If lesions are deemed to be carcinoma in situ, TBNA may have limited value.
| Footnotes |
|---|
Abbreviations:BB = brush biopsy; BW = bronchial washings; CDP = conventional diagnostic procedures; CDP + TBNA = combination of conventional diagnostic procedures and transbronchial needle aspiration; EBB = endobronchial forceps biopsy; EML = exophytic mass lesion; SPD = submucosal and peribronchial disease; TBNA = transbronchial needle aspiration
Received for publication June 25, 1998. Accepted for publication December 19, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. M. Heyer, T. Kagel, S. P. Lemburg, J. W. Walter, J. de Zeeuw, K. Junker, K.-M. Mueller, V. Nicolas, and T. T. Bauer Transbronchial Biopsy Guided by Low-Dose MDCT: A New Approach for Assessment of Solitary Pulmonary Nodules Am. J. Roentgenol., October 1, 2006; 187(4): 933 - 939. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Caglayan, U. A. Akturk, A. Fidan, B. Salepci, S. Ozdogan, G. Sarac, and E. Torun Transbronchial Needle Aspiration in the Diagnosis of Endobronchial Malignant Lesions: A 3-Year Experience Chest, August 1, 2005; 128(2): 704 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kanoh, T. Miyazawa, N. Kurimoto, Y. Iwamoto, Y. Miyazu, and N. Kohno Endobronchial Ultrasonography Guidance for Transbronchial Needle Aspiration Using a Double-Channel Bronchoscope Chest, July 1, 2005; 128(1): 388 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H. Diacon, M. M. Schuurmans, J. Theron, K. Brundyn, M. Louw, C. A. Wright, and C. T. Bolliger Transbronchial Needle Aspirates: Comparison of Two Preparation Methods Chest, June 1, 2005; 127(6): 2015 - 2018. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-H. Hsu, C.-C. Liu, and J.-S. Ko Education and Experience Improve the Performance of Transbronchial Needle Aspiration: A Learning Curve at a Cancer Center Chest, February 1, 2004; 125(2): 532 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schreiber and D. C. McCrory Performance Characteristics of Different Modalities for Diagnosis of Suspected Lung Cancer: Summary of Published Evidence Chest, January 1, 2003; 123(1_suppl): 115S - 128S. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. White, E. A. Weiner, P. Patel, and E. J. Britt Transbronchial Needle Aspiration : Guidance With CT Fluoroscopy Chest, December 1, 2000; 118(6): 1630 - 1638. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. B. S. Prakash Advances in Bronchoscopic Procedures Chest, November 1, 1999; 116(5): 1403 - 1408. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |